SUBSCRIBE
SUBSCRIBE

AstraZeneca

NEWS
Biotech Bay
Drug Companies Lose Protections on Facebook; Johnson & Johnson, AstraZeneca PLC Decide to Close Pages
August 15, 2011
 · 
1 min read
Research into Brain Disorders Under Threat as Drug Firms Like GlaxoSmithKline and AstraZeneca PLC Pull Out
June 14, 2011
 · 
1 min read
Job Trends
Big Pharma, Including Pfizer Inc. and AstraZeneca PLC Strips Down Broken R&D Engine
May 12, 2011
 · 
1 min read
Job Trends
Drug Makers Including AstraZeneca PLC and Sanofi (France) Replace Reps With Digital Tools
May 10, 2011
 · 
1 min read
Pharm Country
AstraZeneca PLC’s $6 Billion Stomach Ache: Nexium Causes Bone Fractures
April 22, 2011
 · 
1 min read
Biotech Beach
Drugmakers, Including AstraZeneca PLC, Novartis AG and Eli Lilly and Company See Pain from Reform and Prices in 2011
January 28, 2011
 · 
1 min read
EU Price Cuts and U.S. Reform Weigh on Big Pharma Including Johnson & Johnson and AstraZeneca PLC
January 24, 2011
 · 
1 min read
Pharm Country
Nicotine May Act as Treatment for Some Symptoms of Schizophrenia, Yale University and AstraZeneca PLC Study
January 11, 2011
 · 
1 min read
Cocktails Are Next For Cancer-Drug Makers; Big Pharma Like Roche Holding AG,AstraZeneca PLC, and Sanofi-Aventis (France) Turns to the Multi-drug Approach that Transformed AIDS
August 27, 2010
 · 
1 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
June 26, 2026
 · 
10 min read
Press Releases
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
June 18, 2026
 · 
7 min read
Press Releases
AstraZeneca Joins ZERO Prostate Cancer’s Historic ‘Blitz the Barriers’ Initiative as a Founding Partner
June 15, 2026
 · 
3 min read
Press Releases
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
June 14, 2026
 · 
19 min read
Press Releases
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
June 8, 2026
 · 
7 min read
Press Releases
Leica Biosystems Announces Expansion of Collaboration to Scale Precision Medicine and Develop AI-Powered Diagnostics
June 3, 2026
 · 
4 min read
Press Releases
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
June 1, 2026
 · 
7 min read
Press Releases
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
May 29, 2026
 · 
19 min read
Press Releases
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
May 24, 2026
 · 
19 min read
Press Releases
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
May 24, 2026
 · 
19 min read
Load More